Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Crispr Therapeutics Ag (NQ: CRSP )

50.76 +4.37 (+9.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Crispr Therapeutics Ag

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
29 30 Next >
3 High-Growth Biotech Stocks Poised for Success in 2023
If you look for growth opportunities wherever you can find them, there are some high-growth biotech stocks that could present an opportunity 
Via InvestorPlace
The Top Healthcare Stocks to Buy With $100
A small investment now may bring big results over time. 
Via The Motley Fool
Why CRISPR Therapeutics Stock Is Marching Higher Today
This gene-editing stock has been heating up over the past week. 
Via The Motley Fool
Why Shares of Editas Medicine Rose Monday
The company is benefiting from positive news affecting other gene-editing stocks. 
Via The Motley Fool
What 14 Analyst Ratings Have To Say About CRISPR Therapeutics
Via Benzinga
Better Growth Stock: Axsome vs. CRISPR Therapeutics
These companies are both in the early days of their growth stories. 
Via The Motley Fool
Is CRISPR Therapeutics Stock a Buy Now?
The biotech could soon be a commercial-stage company. 
Via The Motley Fool
CRISPR Therapeutics Is an Interesting 'Gene Editing Play for 2023' With Significant Upside, Says Analyst
Via Benzinga
Why Shares of CRISPR Therapeutics Jumped Thursday
An independent drug-pricing group said that a $1.9 million cost for the company's exa-cel therapy would be cost-effective. 
Via The Motley Fool
Cathie Wood Just Bought More CRISPR Therapeutics (CRSP) Stock
Shares of CRSP stock are moving higher following an initiation of coverage by Cantor Fitzgerald and continued buys from Cathie Wood. 
Via InvestorPlace
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks. 
Via InvestorPlace
$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
Via Benzinga
Where Will CRISPR Therapeutics Be in 5 Years?
Could CRISPR Therapeutics be the next big healthcare stock? 
Via The Motley Fool
CRISPR Stock: Bull vs. Bear
CRISPR's first approved product may be right around the corner. 
Via The Motley Fool
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
2 Nasdaq Growth Stocks That Are Screaming Buys in April
Massive drivers of fresh earnings are drawing closer, and risks are declining. 
Via The Motley Fool
These Up-and-Coming Stocks Are Screaming Buys Right Now
Both companies could deliver revenue and share price growth over the long term. 
Via The Motley Fool
Could This Move Make Vertex's Next Blockbuster Even Bigger?
Vertex is showing it can branch out beyond its cystic fibrosis specialty. 
Via The Motley Fool
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity?
The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.  
Via Benzinga
5 S&P 500 Stocks Showing Strength As Recession Fears Rise
Medical stocks are holding up amid economic and market uncertainty. 
Via Investor's Business Daily
What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio
Both biotechs are aiming for the same markets, but they are not equally risky. 
Via The Motley Fool
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
Neither stock is a good choice for those who can't handle a lot of risk. 
Via The Motley Fool
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
Via Benzinga
2 Under-the-Radar Biotech Stocks to Buy in 2023
Both companies have game-changing product portfolios that should result in stock price growth. 
Via The Motley Fool
Vertex Is 1 Step Closer to Bringing a New Blockbuster to Market. Time to Buy?
Vertex shares are on the rise. 
Via The Motley Fool
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
The 10 Best Stocks to Buy in April 2023
Here are 10 stocks to buy now that could unlock explosive gains in your growth-stock portfolio. 
Via The Motley Fool
Here's a New Million-Dollar Reason to Buy CRISPR Therapeutics
Together, the companies could produce a game-changing product. 
Via The Motley Fool
5 Bargain-Basement Stocks to Buy Right Now
Down markets offer us something very positive: deals on quality companies. 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.